Detalhe da pesquisa
1.
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Oncologist
; 26(2): e270-e278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33215787
2.
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.
Prostate Cancer Prostatic Dis
; 25(3): 479-483, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34294873